1. Epigenetics
  2. Histone Demethylase

CPI-455 

Cat. No.: HY-100421 Purity: >98.0%
Data Sheet SDS Handling Instructions

CPI-455 is a specific KDM5 inhibitor.

For research use only. We do not sell to patients.
CPI-455 Chemical Structure

CPI-455 Chemical Structure

CAS No. : 1628208-23-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $99 In-stock
5 mg $90 In-stock
10 mg $150 In-stock
25 mg $330 In-stock
50 mg $600 In-stock
100 mg $1000 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

CPI-455 is a specific KDM5 inhibitor.

IC50 & Target

KDM5[1]

In Vitro

CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4 trimethylation (H3K4me3) and decreases the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents[1]. CPI-455, with high measured affinity for the target KDM5 proteins. Within 24 hours, increases in H3K4me3, but not H3K4me2, are observed after exposure to either of the two active compounds, CPI-455 and CPI-766, in a dosedependent manner. IC50 calculation for KDM5 Inhibitor CPI0455 in 3 luminal breast cancer cell lines MCF-7, T-47 and EFM-19 are 35.4, 26.19 and 16.13 μM, respectively[2].

References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 3.5931 mL 17.9656 mL 35.9312 mL
5 mM 0.7186 mL 3.5931 mL 7.1862 mL
10 mM 0.3593 mL 1.7966 mL 3.5931 mL
Please refer to the solubility information to select the appropriate solvent.
Cell Assay
[2]

CPI-455 is dissolved in DMSO (10 mM) and stored (-20°C), and then diluted with appropriate medium before use[1].

MCF-7 is a luminal breast cancer cell line. MCF-7 is grown in MEM supplemented with 10% fetal bovine serum (FBS) and is incubated at 37°C with a 5% CO2 atmosphere. For each treatment condition, 2.5×105 MCF-7 cells are plated in T25 flask and allowed to rest overnight. The following day, the media is aspirated and replaced with media containing DAC at a final concentration of 62.5 nM. DAC media is aspirated and replaced every 24 hours for a total treatment time of 72 hours. Following DAC treatment, media is aspirated and replaced with media supplemented with 2% FBS containing KDM5 inhibitors (e.g., CPI-455) at a final concentration of 9.375 μM. Cells are harvested following 72 hours of KDM5 inhibitor treatment[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

278.31

Formula

C₁₆H₁₄N₄O

CAS No.

1628208-23-0

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 34 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CPI-455
Cat. No.:
HY-100421
Quantity: